Cancer cells survive with survivin

Cancer Science

Volumn 99, Issue 9, 2008, Pages 1709-1714

  Yamamoto, Hirofumi ^a   Ngan, Chew Yee ^a   Monden, Morito ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CELECOXIB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; EPIDERMAL GROWTH FACTOR; ETODOLAC; FLAVOPIRIDOL; FLUOROURACIL; GERANYLGERANYLTRANSFERASE 1 INHIBITOR; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NORDIHYDROGUAIARETIC ACID; NU 6140; OXALIPLATIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; SILYMARIN; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; THREONINE; TRANSCRIPTION FACTOR 7; TRANSFERASE INHIBITOR; TRICHOSTATIN A; UNINDEXED DRUG; VASCULOTROPIN;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG TARGETING; ESOPHAGUS CANCER; HUMAN; LUNG SMALL CELL CANCER; MITOSIS INHIBITION; OVARY CANCER; PANCREAS CANCER; POLYPLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION REGULATION; UPREGULATION;

CELL CYCLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; UP-REGULATION;

EID: 50149115578     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00870.x     Document Type: Review

References (89)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
2. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
3. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54.
4. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-10.
5. Tamm I, Wang Y, Sausville E et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, Caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-20.
6. Lu B, Mu Y, Cao C, Zeng F et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004; 64: 2840-5.
7. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 2004; 6: 29-40.
8. Shin S, Sung BJ, Cho YS et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochem 2001; 40: 1117-23.
9. Sun C, Nettesheim D, Liu Z, Olejniczak ET. Solution structure of human survivin and its binding interface with smac/Diablo. Biochem 2005; 44: 11-17.
10. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in survivin targeted melanoma cells. Oncogene 2004; 23: 39-48.
11. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL. Human survivin is a kinetochore-associated passenger protein. J Cell Biol 2000; 151: 1575-81.
12. Lens SMA, Wolthuis RMF, Klompmaker R et al. Survivin is required for a sustained spindle checkpoint arrest in response to lack of tension. EMBO J 2003; 22: 2934-47.
13. Yang D, Welm A, Bishop M. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA 2004; 101: 15.100-5.
14. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4: 592-603.
15. Ivanov A, Cragg MS, Erenpreisa J, Emzinsh D, Lukman H, Illidge TM. Endoploidy cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. J Cell Sci 2003; 116: 4095-106.
16. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362: 205-9.
17. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 344: 305-11.
18. Esteve PO, Chin HG, Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 2007; 282: 2615-25.
19. Gritsko T, Williams A, Turkson J et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12: 11-19.
20. Duan Z, Bradner JE. Greenberg et al. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res 2006; 12: 6844-52.
21. Ngan CY, Yamamoto H, Takagi A et al. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 2008; 99: 129-39.
22. Peng XH, Karna P, Cao Z, Jiang B-H, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1α signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006; 281: 25.903-14.
23. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 2000; 113: 4363-71.
24. O'Connor DS, Grossman D, Plescia J et al. Regulation of apoptosis at cell division by p34 cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97: 13.103-7.
25. Newcomb EW. Flavopiridol: Pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004; 15: 411-19.
26. Pennati M, Campbell AJ, Curto M et al. Potentiaion of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation. Mol Cancer Ther 2005; 4: 1328-37.
27. Fortugno P, Beltrami E, Plescia J et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003; 100: 13.791-6.
28. Dan HC, Jiang K, Coppola D et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets fro geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004; 23: 706-15.
29. Zhou C, Qiu L, Sun Y et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 2006; 29: 269-78.
30. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005; 117: 755-63.
31. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adults tissues. Mol Cancer Ther 2006; 5: 1087-98.
32. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88: 115-19.
33. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-12.
34. Yu J, Leung WK, Ebert MP et al. Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer 2002; 87: 91-7.
35. Sarela AI, Macadam RCA, Farmery SM, Markham AF, Guillou PJ. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000; 46: 645-50.
36. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001; 92: 271-8.
37. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJ. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002; 86: 886-92.
38. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol 2002; 11: 33-40.
39. Ito T, Shiraki K, Sugimoto K et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000; 31: 1080-5.
40. Nasu S, Yagihashi A, Izawa A et al. Survivin mRNA expression in patients with breast cancer. Anticancer Res 2002; 22: 1839-43.
41. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-34.
42. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma correlation with apoptotic markers and prognosis. Mod Pathol 2003; 16: 574-83.
43. Monzo M, Rosell R, Felip E et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-4.
44. Lehner R, Lucia MS, Jarboe EA et al. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morph 2002; 10: 134-8.
45. Mori A, Wada H, Nishimura Y, Okamoto T, Takemoto Y, Kakishita E. Expression of the antiapoptosis gene survivin in human leukemia. Int J Hematol 2002; 75: 161-5.
46. Bao R, Connoly DC, Murphy M et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94: 522-8.
47. + T cells in colorectal cancer patients. Cancer Res 2003; 63: 4507-15.
48. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001; 61: 869-72.
49. Schmidt SM, Schag K, Muller MR et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102: 571-6.
50. Kawasaki H, Toyoda M, Shinohara H et al. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer 2001; 91: 2026-32.
51. Bhanot U, Heydrich R, Moller P, Hasel C. Survivin expression in pancreatic intraepithelial neoplasia (PanIN): Steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol 2006; 30: 754-9.
52. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 2002; 21: 315-20.
53. Chakravarti A, Noll E, Black PM et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 2002; 20: 1063-8.
54. Blanc-Brude OP, Mesri M et al. Therapeutic targeting of the survivin pathway in cancer: Initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9: 2683-92.
55. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002; 99: 4349-54.
56. Ikeguchi M, Kaibara N. Survivin messenger RNA expression is a good prognostic biomarker for oesophageal cancer. Br J Cancer 2002; 87: 883-7.
57. Kato J, Kuwahara Y, Mitani M et al. Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer 2001; 95: 92-5.
58. Zaffaroni N, Pennati M, Colella G et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002; 59: 1406-12.
59. Rodel F, Hoffman J, Distel L et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65: 4881-7.
60. Pyrko P, Soriano N, Kardosh A et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 2006; 5: 19-34.
61. Lin J, Hsiao PW, Chiu TH, Chao JI. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 2005; 70: 658-67.
62. Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis 2007; 28: 1533-42.
63. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting cdc2 and survivin expression. Proc Natl Acad Sci USA 2004; 101: 13.239-44.
64. Inoue T, Shiraki K, Fuke H et al. Proteasome inhibition sensitizes hepatocellular carcinoma cells to TRAIL by suppressing caspase inhibitors and AKT pathway. Anticancer Drugs 2006; 17: 261-8.
65. Radhakrishnan SK, Halasi M, Bhat UG, Kurmasheva RT, Houghton PJ, Gartel AL. Proapoptotic compound ARC targeted Akt and N-myc in neuroblastoma cells. Oncogene 2008; 27: 694-9.
66. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. Cancer Res 2007; 67: 2816-23.
67. Rahman KMW, Li Y, Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,3′-diinolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006; 66: 4952-60.
68. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003; 63: 230-5.
69. Asanuma K, Moriai R, Yajima T et al. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000; 91: 1204-9.
70. Gu CM, Zhu YK, Ma YH et al. Knockdown of survivin gene by vector-based short hairpin RNA technique induces apoptosis and growth inhibition in Burkitt's lymphoma Raji cell line. Neoplasma 2006; 53: 206-12.
71. Pennati M, Binda M, Colella G et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 2004; 23: 386-94.
72. Kamizono J, Nagano S, Murofushi Y et al. Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res 2005; 65: 5284-91.
73. Pennati M, Binda M, Colella G et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J Invest Dermatol 2003; 120: 648-54.
74. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108: 981-90.
75. Pennati M, Colella G, Folini M, Citti I, Daidone MG, Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J Clin Invest 2002; 109: 285-6.
76. Yonesaka K, Tamura K, Kurata T et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006; 118: 812-20.
77. Zhang M, Mukherjee N, Bermudez RS et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 2005; 64: 293-302.
78. Kami K, Doi R, Koizumi M et al. Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 2005; 138: 299-305.
79. Paduano F, Villa R, Pennati M et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006; 5: 179-86.
80. Plescia J, Salz W, Xia F et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005; 7: 457-68.
81. Fujie Y, Yamamoto H, Ngan CY et al. Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells. Jpn J Clin Oncol 2005; 35: 453-63.
82. Gu J, Yamamoto H, Lu X et al. Low dose oxaliplatin enhances the antitumor efficacy of paclitaxel in human gastric cancer cell lines. Digestion 2006; 74: 19-27.
83. Caldas H, Jaynes FO, Boyer MW, Hammond S, Altura RA. Survivin and granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther 2006; 5: 693-703.
84. Wang R, Lin F, Wang X et al. The therapeutic potential of survivin promoter-driven siRNA on suppressing tumor growth and enhancing radiosensitivity of human cervical carcinoma cells via downregulating hTERT gene expression. Cancer Biol Ther 2007; 6: 1295-301.
85. Zhang HZ, Wang Y, Gao P et al. Silencing stathmin gene expression by survivin promoter-driven siRNA vector to reverse malignant phenotype of tumor cells. Cancer Biol Ther 2006; 5: 1457-61.
86. Cho HI, Kim EK, Park SY, Lee SK, Hong YK, Kim TG. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett 2007; 258: 189-98.
87. Idenoue A, Hirohashi Y, Torigoe T et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005; 11: 1474-82.
88. Xiang R, Mizutani N, Luo Y et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005; 65: 553-61.
89. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55: 1294-8.